skip to main content

irAEs — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardImmunotherapy & Targeted TherapyirAEsSCE Medical Oncology

During cycle 3 of capecitabine, a patient develops a first episode of painful palmar erythema and swelling that limits instrumental activities of daily living but no blistering or ulceration. What dose action is licensed?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Interrupt capecitabine until toxicity resolves to grade 0–1, then restart at 100% of the starting dose for this first grade 2 episode

This is a first grade 2 hand-foot syndrome episode. The SmPC dose table specifies interruption until grade 0–1 and resumption at 100% for the first grade 2 occurrence; 75% and 50% apply to the second and third occurrences. The earlier explanation incorrectly mandated immediate dose reduction.

Reference: Capecitabine 500 mg UK summary of product characteristics (Current UK SmPC, accessed August 2026): https://www.medicines.org.uk/emc/product/14591/smpc